Anixa Biosciences Accounts Receivables 2011-2026 | ANIX

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Anixa Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
173 K	270 K	46 K	-	-	66.5 K	-	-	-	-	400 K	175 K	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
400 K	46 K	188 K

Quarterly Accounts Receivables Anixa Biosciences

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	173 K	410 K	218 K	391 K	270 K	334 K	256 K	-	47 K	-	-	-	-	-	-	22.3 K	2.23 K	5.95 K	32.3 K	-	66.5 K	66.5 K	66.5 K	-	307 K	307 K	-	-	-	221 K	-	-	-	-	-	45 K	-	-	-	-	400 K	400 K	400 K	-	175 K	175 K	175 K	-	7 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
410 K	2.23 K	191 K

Accounts Receivables of other stocks in the Diagnostics research industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Akumin AKU	114 M	-	-17.87 %	$ 25.9 M	Canada
Accelerate Diagnostics AXDX	2.42 M	-	-61.36 %	$ 2.46 M	USA
Burning Rock Biotech Limited BNR	88.2 M	$ 22.01	11.81 %	$ 237 M	China
Biocept BIOC	2.15 M	-	-13.05 %	$ 7.29 M	USA
Chembio Diagnostics CEMI	6.54 M	-	0.22 %	$ 16.8 M	USA
Co-Diagnostics CODX	304 K	$ 5.72	2.88 %	$ 168 M	USA
BioNano Genomics BNGO	4.75 M	$ 1.62	1.89 %	$ 2.06 M	USA
DarioHealth Corp. DRIO	3.16 M	$ 12.64	20.15 %	$ 359 M	Israel
DexCom DXCM	974 M	$ 67.67	1.7 %	$ 26.1 B	USA
Castle Biosciences CSTL	51.2 M	$ 38.51	-0.08 %	$ 1.07 B	USA
Exact Sciences Corporation EXAS	249 M	$ 101.53	-0.21 %	$ 18.8 B	USA
Danaher Corporation DHR	3.54 B	$ 234.56	1.82 %	$ 171 B	USA
DermTech DMTK	2.58 M	-	-11.32 %	$ 2.94 M	USA
Fulgent Genetics FLGT	69 M	$ 25.48	-0.43 %	$ 770 M	USA
Enzo Biochem ENZ	3.99 M	-	-8.98 %	$ 14.8 K	USA
Global Cord Blood Corporation CO	416 M	-	-	$ 399 M	China
CareDx, Inc CDNA	51.1 M	$ 20.02	4.6 %	$ 1.08 B	USA
IQVIA Holdings IQV	3.2 B	$ 233.99	3.82 %	$ 42.4 B	USA
Guardant Health GH	110 M	$ 102.55	0.79 %	$ 12.6 B	USA
Heska Corporation HSKA	29.5 M	-	-	$ 1.31 B	USA
HTG Molecular Diagnostics HTGM	1.42 M	-	-20.0 %	$ 1.06 M	USA
Aspira Women's Health AWH	1.24 M	-	-6.19 %	$ 10.5 M	USA
Illumina ILMN	735 M	$ 140.15	4.32 %	$ 22.3 B	USA
Charles River Laboratories International CRL	721 M	$ 208.19	2.86 %	$ 10.7 B	USA
Myriad Genetics MYGN	121 M	$ 6.19	0.73 %	$ 561 M	USA
NeoGenomics NEO	151 M	$ 12.18	3.53 %	$ 1.54 B	USA
Neogen Corporation NEOG	153 M	$ 7.3	4.21 %	$ 1.58 B	USA
Natera NTRA	244 M	$ 235.89	3.08 %	$ 23.2 B	USA
Quest Diagnostics Incorporated DGX	1.3 B	$ 173.85	0.13 %	$ 19.3 B	USA
Biodesix BDSX	8.6 M	$ 6.05	-6.35 %	$ 785 M	USA
OPKO Health OPK	118 M	$ 1.26	-0.39 %	$ 874 M	USA
Laboratory Corporation of America Holdings LH	1.94 B	$ 253.05	0.55 %	$ 21.2 B	USA
Motus GI Holdings MOTS	76 K	-	-34.28 %	$ 263 K	Israel
ICON Public Limited Company ICLR	1.34 B	$ 197.18	4.51 %	$ 16.3 B	Irlanda
IDEXX Laboratories IDXX	474 M	$ 682.72	1.9 %	$ 56.3 B	USA
Lantheus Holdings LNTH	321 M	$ 69.25	2.94 %	$ 4.79 B	USA
Pacific Biosciences of California PACB	36.6 M	$ 1.96	6.52 %	$ 497 M	USA
Agilent Technologies A	1.17 B	$ 142.17	3.08 %	$ 43.2 B	USA
Mettler-Toledo International MTD	687 M	$ 1 439.83	2.01 %	$ 30.6 B	Schweiz
Organovo Holdings ONVO	30 K	-	-2.3 %	$ 19.4 M	USA
Biomerica BMRA	731 K	$ 2.56	1.19 %	$ 5.88 M	USA